# A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.

> **NCT00353808** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 112 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** [S,S]-Reboxetine

## Key facts

- **NCT ID:** NCT00353808
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 112 (ACTUAL)
- **Why stopped:** This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.
- **Last updated:** 2011-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00353808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00353808, "A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00353808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*